Trial Profile
Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary) ; Fluconazole; Micafungin
- Indications Invasive candidiasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors SCYNEXIS
- 15 Jul 2019 Results assessing efficacy and safety of ibrexafungerp dose in subjects with invasive candidiasis, published in the Journal of Antimicrobial Chemotherapy.
- 24 May 2017 Data from this trial will be presented at the ASM Microbe 2017, according to a SCYNEXIS media release.
- 25 Apr 2017 Results assessing safety, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases